全球疫苗四大巨头之一赛诺菲3.5亿欧元在加拿大建立新疫苗工厂

2018-04-15 MedSci MedSci原创

赛诺菲于4月12日宣布将斥资3.5亿欧元在加拿大多伦多建立新疫苗工厂,这是该公司有史以来在单一制造工厂中最大规模的一次投资,此举也更加凸显赛诺菲巴斯德疫苗业务对赛诺菲的重要性。

全球疫苗四大巨头(默沙东、葛兰素史克、赛诺菲和辉瑞)之一的赛诺菲,其明星疫苗产品潘立欣(DTPa-Hib-脊灰五联苗)融合百日咳、白喉、破伤风、脊髓灰质炎以及b型流感嗜血杆菌,共五种传染性疾病的预防性疫苗于一体。总共只需4次接种,比国产疫苗减少了8次,在国内非常受欢迎。国际市场也维持稳定的销量,2016年销售额达15亿欧元,占全球疫苗销售额的6%。

赛诺菲于4月12日宣布将斥资3.5亿欧元在加拿大多伦多建立新疫苗工厂,这是该公司有史以来在单一制造工厂中最大规模的一次投资,此举也更加凸显赛诺菲巴斯德疫苗业务对赛诺菲的重要性。

这家多伦多新工厂将专注于生产无细胞百日咳(5-acP)抗原,灭活脊髓灰质炎病毒(IPV)抗原和b型流感嗜血杆菌抗原。赛诺菲表示新工厂在2021年一旦完工,也将配备生产白喉和破伤风抗原。

赛诺菲全球工业事务负责人Philippe Luscan表示:"该项目是赛诺菲全球工业网络最重要的投资之一,表明了我们对制造卓越的持续承诺,并更好地为我们的疫苗组合服务于世界各地的人们。"

原始出处:


此文系梅斯医学(MedSci)原创整理编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1693226, encodeId=64be169322625, content=<a href='/topic/show?id=523b585602f' target=_blank style='color:#2F92EE;'>#新疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58560, encryptionId=523b585602f, topicName=新疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8329353204, createdName=gous, createdTime=Tue Jul 31 11:34:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312576, encodeId=7de413125e66a, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue Apr 17 03:34:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306111, encodeId=a0e1306111ac, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Sun Apr 15 21:06:44 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306088, encodeId=549a306088ca, content=嘿嘿.真是让人耳目一新.感觉望尘莫及似的.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Apr 15 18:28:13 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306050, encodeId=1d2630605094, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Apr 15 15:35:27 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306037, encodeId=cac230603ec2, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Apr 15 13:53:31 CST 2018, time=2018-04-15, status=1, ipAttribution=)]
    2018-07-31 gous
  2. [GetPortalCommentsPageByObjectIdResponse(id=1693226, encodeId=64be169322625, content=<a href='/topic/show?id=523b585602f' target=_blank style='color:#2F92EE;'>#新疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58560, encryptionId=523b585602f, topicName=新疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8329353204, createdName=gous, createdTime=Tue Jul 31 11:34:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312576, encodeId=7de413125e66a, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue Apr 17 03:34:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306111, encodeId=a0e1306111ac, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Sun Apr 15 21:06:44 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306088, encodeId=549a306088ca, content=嘿嘿.真是让人耳目一新.感觉望尘莫及似的.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Apr 15 18:28:13 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306050, encodeId=1d2630605094, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Apr 15 15:35:27 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306037, encodeId=cac230603ec2, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Apr 15 13:53:31 CST 2018, time=2018-04-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1693226, encodeId=64be169322625, content=<a href='/topic/show?id=523b585602f' target=_blank style='color:#2F92EE;'>#新疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58560, encryptionId=523b585602f, topicName=新疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8329353204, createdName=gous, createdTime=Tue Jul 31 11:34:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312576, encodeId=7de413125e66a, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue Apr 17 03:34:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306111, encodeId=a0e1306111ac, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Sun Apr 15 21:06:44 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306088, encodeId=549a306088ca, content=嘿嘿.真是让人耳目一新.感觉望尘莫及似的.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Apr 15 18:28:13 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306050, encodeId=1d2630605094, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Apr 15 15:35:27 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306037, encodeId=cac230603ec2, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Apr 15 13:53:31 CST 2018, time=2018-04-15, status=1, ipAttribution=)]
    2018-04-15 周周人

    学习.

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1693226, encodeId=64be169322625, content=<a href='/topic/show?id=523b585602f' target=_blank style='color:#2F92EE;'>#新疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58560, encryptionId=523b585602f, topicName=新疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8329353204, createdName=gous, createdTime=Tue Jul 31 11:34:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312576, encodeId=7de413125e66a, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue Apr 17 03:34:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306111, encodeId=a0e1306111ac, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Sun Apr 15 21:06:44 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306088, encodeId=549a306088ca, content=嘿嘿.真是让人耳目一新.感觉望尘莫及似的.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Apr 15 18:28:13 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306050, encodeId=1d2630605094, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Apr 15 15:35:27 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306037, encodeId=cac230603ec2, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Apr 15 13:53:31 CST 2018, time=2018-04-15, status=1, ipAttribution=)]
    2018-04-15 虈亣靌

    嘿嘿.真是让人耳目一新.感觉望尘莫及似的.学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1693226, encodeId=64be169322625, content=<a href='/topic/show?id=523b585602f' target=_blank style='color:#2F92EE;'>#新疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58560, encryptionId=523b585602f, topicName=新疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8329353204, createdName=gous, createdTime=Tue Jul 31 11:34:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312576, encodeId=7de413125e66a, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue Apr 17 03:34:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306111, encodeId=a0e1306111ac, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Sun Apr 15 21:06:44 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306088, encodeId=549a306088ca, content=嘿嘿.真是让人耳目一新.感觉望尘莫及似的.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Apr 15 18:28:13 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306050, encodeId=1d2630605094, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Apr 15 15:35:27 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306037, encodeId=cac230603ec2, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Apr 15 13:53:31 CST 2018, time=2018-04-15, status=1, ipAttribution=)]
    2018-04-15 131****1460

    学习了受益匪浅

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1693226, encodeId=64be169322625, content=<a href='/topic/show?id=523b585602f' target=_blank style='color:#2F92EE;'>#新疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58560, encryptionId=523b585602f, topicName=新疫苗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8329353204, createdName=gous, createdTime=Tue Jul 31 11:34:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312576, encodeId=7de413125e66a, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue Apr 17 03:34:00 CST 2018, time=2018-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306111, encodeId=a0e1306111ac, content=学习., beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDcVAydhtcpjiaxLrZD7Eb5YnKPgf7ypGpfyl7FflFyAenvQLbib6T0LPXIhXo9SPNPXYYFFJbEgykztwJ0HQ61I3F9GxIVKWsgQ/0, createdBy=f38d2052407, createdName=周周人, createdTime=Sun Apr 15 21:06:44 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306088, encodeId=549a306088ca, content=嘿嘿.真是让人耳目一新.感觉望尘莫及似的.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sun Apr 15 18:28:13 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306050, encodeId=1d2630605094, content=学习了受益匪浅, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Sun Apr 15 15:35:27 CST 2018, time=2018-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306037, encodeId=cac230603ec2, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Apr 15 13:53:31 CST 2018, time=2018-04-15, status=1, ipAttribution=)]
    2018-04-15 sunfeifeiyang

    0

相关资讯

赛诺菲以39亿欧元收购Ablynx

赛诺菲宣布打算通过价值约39亿欧元的交易,购买比利时制药商Ablynx,并击败诺和诺德(Novo Nordisk)到达胜利的终点。Ablynx专注于纳米抗体的发现和开发,纳米抗体是新一代专有生物制剂,为血液学,炎症,免疫肿瘤学和呼吸系统等广泛的治疗领域提供超过45种专有和合作的候选药物。它的八个纳米抗体已进入临床开发阶段,其最先进的产品caplacizumab已经在欧盟提交,预计将在今年上半年在美

赛诺菲中国荣膺“中国杰出雇主2018”认证

/* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li

赛诺菲与阿里健康携手推出“指尖上的安心”用药安全与疾病管理项目

/* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_

FDA解除对赛诺菲血友病药物的临床控制

美国食品和药物管理局在9月份取消了对该方案的临床控制权之后,赛诺菲和Alnylam的血友病治疗药物fitusiran面临的一个主要障碍已经被消除。以抗凝血酶(AT)为靶点的RNA干扰药物现在可以在没有抑制剂的情况下恢复血友病A和B患者的II期和III期临床试验,在一名血友病患者A的开放标签II期试验中出现一例致命血块后暂停。这两家公司制定了一项计划,以减少其他患者血栓形成的风险,并将其提交给FDA

真实世界的数据支持赛诺菲的Toujeo用于I型糖尿病

赛诺菲公布了来自英国真实世界的研究数据,显示其长效基础胰岛素类似物Toujeo在治疗I型糖尿病患者中的功效。这些数据首次在芝加哥内分泌协会第100届年会暨博览会ENDO 2018上发布,表明该药物与患有该病症的患者的HbA1c的显着改善,具有统计学意义,平均差异从基线至六个月的-4.4毫摩尔/摩尔。该研究还显示,在Toujeo(Gla-300)开始治疗后报告糖尿病酮症酸中毒(DKA)或严重低血糖的

赛诺菲将Dupixent用于严重哮喘

美国监管机构已接受Sanofi / Regeneron的生物制剂Dupixent作为某些成人和青少年中度至重度哮喘的辅助治疗药物。Dupixent是一种人类单克隆抗体,专门用于抑制IL-4和IL-13的信号传导,IL-4和IL-13是导致中度至重度哮喘中II型炎症的两种关键信号蛋白。该药物已经在市场上用于治疗特应性皮炎。哮喘的提交资料包括III期LIBERTY ASTHMA VENTURE研究的数